Effect of Vitamin D on Cardiovascular Metabolic Risk in Overweight/Obesity Adolescents in China

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age10-16
SponsorAnhui Medical University

About this trial

The goal of this randomized controlled clinical trial is to investigate the effects of vitamin D3 supplementation on cardiometabolic risk in Chinese adolescents with overweight/obesity and vitamin D deficiency. The main question it aims to answer whether vitamin D3 supplementation can improve cardiovascular metabolic health.

Participants in the intervention group will receive vitamin D3. The control group will receive vitamin D placebo.

Researchers will compare the change in cardiometabolic risk from baseline to post-intervention at 12 weeks between the intervention and control groups.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Students whose caregivers signed informed consents;

Students with serum 25(OH)D concentration of 12-20 ng/mL;

Students with overweight or obesity.

Disqualifiers

Students with any disease that affects vitamin D metabolism (e.g., functional/organic brain disease, severe infectious disease, chronic gastrointestinal disease, hepatic or renal insufficiency, etc.);

Students with known chronic disease (e.g., cardiovascular disease); use of vitamin D supplements in the past 3 months;

Students with allergies to vitamin D or soybean oil ingredients.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Dietary Supplement: Vitamin D3

    Drug

    2000 IU per day for 6 weeks (two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU (one capsule of 800 IU) per day for 6 weeks.

  • Dietary Supplement: Vitamin D3 placebo

    Drug

    Three capsules for 6 weeks, followed by one capsule for 6 weeks.

Treatment groups

130 Participants
are divided into 2 treatment groups
Group A: ExperimentalExperimental treatment 1 intervention
Group B: Placebo ComparatorPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in cardiometabolic risk scores

The cardiovascular metabolic risk scores was the sum of the sex-specific standardized z-score for 5 indicators: WC, MAP (MAP=1/3\*SBP+2/3\*DBP), HDL-C (HDL-C value multiplied by -1), TG, and fasting glucose. A higher cardiometabolic risk scores indicates a higher individual cardiometabolic risk. Change in cardiometabolic risk scores from pre to post-intervention were compared between randomized groups, which was the primary outcome of this study

Time frame
From randomization to the end of intervention at 3 months

Secondary outcomes

1

BMI

Measurements were taken by trained researchers using a height and weight meter. The instrument was calibrated before the measurement and the subjects were asked to remove their shoes and wear light clothes during the measurement. We used weight in kilograms and height in metres to calculate BMI. The unit of BMI is kg/m\^2, BMI=Weight/(Height\*2) in kg/m\^2.

Time frame
From randomization to the end of intervention at 3 months
2

Waist circumference and Sum of skinfold thickness

Subcutaneous fat thickness was measured in the upper arm (at the midpoint of the line between the acromion point and the ulnar humerus), subscapularis (1 cm below the subscapularis) and abdomen (junction of the right midclavicular line and the umbilical level) using a skinfold thickness gauge after uniform training, with the results expressed in mm to one decimal place, and all of which required zeroing and pressure testing work of the skinfold thickness gauge before use. Waist circumference was measured using a corrected tape measure, circling horizontally along the midpoints of the lower edge of the ribs and the upper edge of the hip bone, and readings were recorded at the end of expiration to an accuracy of 0.1 cm.

Time frame
From randomization to the end of intervention at 3 months
3

Blood pressure

The researchers measured systolic and diastolic blood pressure using an Omron HEM-7124 digital sphygmomanometer. Measurements were taken with the subject in a sitting position and started after 10 minutes of sitting still, with 2 measurements taken at 5 minute intervals. The average of the two measurements will be taken.

Time frame
From randomization to the end of intervention at 3 months
4

Blood glucose and lipid

After each subject fasted overnight, the next day two professional nurses took their fasting blood samples by venipuncture, the blood samples were stored in an insulated box with ice packs, and all the samples were immediately transported to the laboratory to be tested by the professionals, and the indexes measured included fasting blood glucose, total cholesterol, triglycerides, HDL cholesterol and LDL cholesterol.

Time frame
From randomization to the end of intervention at 3 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.